Clareo Health | Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Orexigen Therapeutics, Inc
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Female or male, 18 to 60 years old
Body mass index (BMI) ≥30 kg/m2 and ≤45 kg/m2 for subjects with uncomplicated obesity, or BMI ≥27 kg/m2 and ≤45 kg/m2 for subjects with dyslipidemia and/or controlled hypertension
You may not be if
History of type 1 or type 2 diabetes mellitus diagnosis
Myocardial infarction within 6 months prior to screening
Angina pectoris Grade III or IV as per the Canadian Cardiovascular Society grading scheme
Clinical history of large vessel cortical strokes, including ischemic and hemorrhagic strokes (i.e., transient ischemic attack is not exclusionary)
History (within the last 20 years) of seizures, cranial trauma, bulimia, anorexia nervosa, or other conditions that predispose subjects to seizures
Past or planned surgical or device intervention (e.g., gastric banding) for obesity
